Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy

Annals of Surgical Oncology

Volumn 22, Issue 11, 2015, Pages 3409-3413

  Evans, Douglas B ^a   George, Ben ^a   Tsai, Susan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CELIAC ARTERY; CHEMORADIOTHERAPY; EDITORIAL; HEPATIC ARTERY; HUMAN; METASTASIS; PANCREAS CANCER; PERINEURIUM; PHYSICIAN; PORTAL VEIN; PREOPERATIVE PERIOD; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC VEIN; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; NEOADJUVANT THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; RADIOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941417302     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4649-2     Document Type: Editorial

References (13)

1. Tsai S, George B, Christians KK, Evans DB. Neoadjuvant chemotherapy and radiochemotherapy: is there a survival advantage for pancreatic cancer patients. In Beger HG, Nakao A, Neoptolemos JP, Peng SY, Sarr MG, eds. Pancreatic cancer, cystic neoplasms, and endocrine tumors: diagnosis and management. Oxford: Wiley-Blackwell, 2015
2. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
3. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Martin RG, Fenoglio CF, Evans DB. Thin-section contrast enhanced computed tomography accurately predicts resectability of malignant pancreatic neoplasms. Am J Surg 1994;167: 104-113.
4. Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol. 2005;8(5):377-84.
5. Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol. 2010;17(11):2803-5.
6. Sadot E, Doussot A, O’Reilly E, et al. FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma. Ann Surg Oncol. (2014) 219(4):176
7. Appel BL, Tolat P, Evans DB, Tsai S. Current staging systems for pancreatic cancer. Cancer J. 2012;18(6):539-49.
8. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1736-44.
9. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083-93.
10. Pilgrim CH, Tsai S, Evans DB, Christians KK. Mesocaval Shunting: A Novel Technique to Facilitate Venous Resection and Reconstruction and Enhance Exposure of the Superior Mesenteric and Celiac Arteries during Pancreaticoduodenectomy. J Am Coll Surg. 2013;217(3):e17-20
11. Pilgrim CH, Tsai S, Tolat P, Patel P, Rilling W, Evans DB, Christians KK. Optimal Management of the Splenic Vein at the Time of Venous Resection for Pancreatic Cancer: Importance of the Inferior Mesenteric Vein. J Gastrointest Surg. 2014;18(5):917-21
12. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B, Tolat P, Evans DB. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014;155(5):919-26
13. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? Oncologist. 2014;19(3):266-74.